Santen Pharmaceutical Co., Ltd.

4536

JP3336000009

Pharmaceuticals

Market Closed - Japan Exchange Other stock markets 02:00:00 2024-05-16 am EDT			5-day change	1st Jan Change
1,604 ^JPY	-0.22%		+3.59%	+14.13%

May. 10	Santen Pharmaceutical Intends to Buy Back and Cancel up to 38 Billion Yen Worth of Shares	MT
May. 09	Santen Pharmaceutical Co., Ltd. announces an Equity Buyback for 21,110,000 shares, representing 5.81% for ¥38,000 million.	CI

Santen Pharmaceutical Co., Ltd. Provides Earnings Guidance for the Fiscal Year Ending March 31, 2023

August 04, 2022 at 02:00 am EDT

Santen Pharmaceutical Co., Ltd. provided earnings guidance for the fiscal year ending March 31, 2023. For the period, the company expected revenue of JPY 264,000 million, Operating profit of JPY 34,200 million, net profit for the year of JPY 24,400 million and Basic EPS of JPY 61.96.

Latest news about Santen Pharmaceutical Co., Ltd.

Santen Pharmaceutical Intends to Buy Back and Cancel up to 38 Billion Yen Worth of Shares	May. 10	MT
Santen Pharmaceutical Co., Ltd. announces an Equity Buyback for 21,110,000 shares, representing 5.81% for ¥38,000 million.	May. 09	CI
Santen Pharmaceutical Co., Ltd. Provides Year End Dividend Guidance for the Full Year Ending March 31, 2025	May. 09	CI
Santen Pharmaceutical Co., Ltd. Announces Year End Dividend for the Year Ended March 31, 2024, Payable on June 26, 2024; Provides Dividend Guidance for the End of Second Quarter of 2025	May. 09	CI
Santen Pharmaceutical Co., Ltd. Provides Consolidated Earnings Forecasts for the Fiscal Year Ending March 31, 2025	May. 09	CI
Santen Pharmaceutical Co., Ltd. authorizes a Buyback Plan.	May. 08	CI
Santen Pharmaceutical to Cancel 12 Million Treasury Shares	Mar. 25	MT
Santen Announces Re-Designation Akira Kurokawa as Director of the Board and Chairman from Representative Director of the Board, Chairman, Effective from April 1, 2024	Mar. 25	CI
Tranche Update on Santen Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on May 11, 2023.	Mar. 25	CI
Santen Pharmaceutical Co., Ltd.'s Equity Buyback announced on May 11, 2023, has closed with 12,571,400 shares, representing 3.38% for ¥16,178.35 million.	Mar. 21	CI
Santen Pharmaceutical's Returns to the Black in Fiscal Nine Months	Feb. 08	MT
Santen Pharmaceutical Co., Ltd. Revises Dividend Guidance for the Fiscal Year Ending March 31, 2024	Feb. 08	CI
Jefferies Adjusts Santen Pharmaceutical’s Price Target to 1,700 Yen From 1,650 Yen, Keeps at Buy	Jan. 29	MT
Santen Pharmaceutical Further Repurchases Shares for Over 1 Billion Yen	Jan. 07	MT
Tranche Update on Santen Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on May 11, 2023.	Jan. 05	CI
Santen Pharmaceutical Buys Back Nearly 2 Billion Yen of Shares	Dec. 04	MT
Santen Pharmaceutical’s Fiscal H1 EPS Increases to 69.68 Yen as Net Sales Rise 13.1% to 145.81 Billion Yen; Declares Interim Dividend of 16 Yen Per Share, Maintains Forecast	Nov. 08	MT
Santen Pharmaceutical Co., Ltd. Revises Consolidated Earnings Forecasts for the Fiscal Year Ending March 31, 2024	Nov. 07	CI
Santen Pharmaceutical Co., Ltd. Announces Dividend for the Second Quarter Ended September 30, 2023, Payable on November 30, 2023; Provides Dividend Guidance for the Fiscal Year Ending March 31, 2024	Nov. 07	CI
Santen Pharmaceutical Buys Back 523,400 shares for 772.6 Million Yen in September	23-10-02	MT
Tranche Update on Santen Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on May 11, 2023.	23-10-02	CI
Jefferies Adjusts Santen Pharmaceutical’s Price Target to 1,650 Yen From 1,400 Yen, Keeps at Buy	23-09-21	MT
Santen Pharmaceutical Co., Ltd. Revises Consolidated Earnings Forecasts for the Fiscal Year Ending March 31, 2024	23-09-19	CI
Santen Pharmaceutical Co., Ltd. Provides Dividend Forecasts for Second Quarter of 2024 and the Fiscal Year Ending March 31, 2024	23-08-03	CI
Santen Pharmaceutical Co., Ltd. Provides Consolidated Earnings Forecasts for the Fiscal Year Ending March 31, 2024	23-08-03	CI

Chart Santen Pharmaceutical Co., Ltd.

Duration

Period

More charts

Company Profile

SANTEN PHARMACEUTICAL CO., LTD. is a Japan-based pharmaceutical company engaged in the research, development, manufacturing and sales of pharmaceutical products. The Company has medical pharmaceutical business, OTC drugs business, medical devices business and other businesses. The Company engages in manufacture, sale and clinical development of medical pharmaceutical products, the development, manufacturing and sales of medical equipment, as well as the cleaning business. The Company operates in Japan, Europe, Asia, North America markets.

Sector

Pharmaceuticals

Calendar

2024-06-24 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Ratings for Santen Pharmaceutical Co., Ltd.

Trading Rating

Investor Rating

ESG Refinitiv

B+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

1,607 JPY

Average target price

1,787 JPY

Spread / Average Target

+11.20%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
SANTEN PHARMACEUTICAL CO., LTD.	+14.13%	3.65B
ELI LILLY AND COMPANY	+35.01%	709B
NOVO NORDISK A/S	+30.71%	595B
JOHNSON & JOHNSON	-2.60%	367B
MERCK & CO., INC.	+20.83%	334B
ABBVIE INC.	+5.69%	289B
ASTRAZENECA PLC	+14.13%	239B
NOVARTIS AG	+9.31%	211B
ROCHE HOLDING AG	-3.35%	203B
AMGEN INC.	+10.77%	171B

Other Pharmaceuticals